Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 10 W ELECTROLYTES versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 10 W ELECTROLYTES versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN II 10% W/ ELECTROLYTES vs AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; electrolytes maintain osmotic and acid-base balance.
Provides essential amino acids and dextrose for parenteral nutrition; amino acids serve as substrates for protein synthesis, while dextrose supplies caloric energy.
1-2 g/kg/day (0.1-0.2 g/kg/hour) IV via central line as continuous infusion.
Individualized based on protein and calorie requirements; typical adult dose: 500-2000 mL/day intravenously, infused at a rate not exceeding 200 mL/hour.
None Documented
None Documented
The terminal elimination half-life of individual amino acids varies but is generally short (range 0.5–2 hours) due to rapid uptake and metabolism. Clinically, the half-life of infused amino acids is not a relevant parameter for dosing; rather, infusion rate is adjusted to maintain nitrogen balance.
Variable, dependent on individual amino acids and metabolic state; clinical context reflects continuous infusion without distinct terminal phase.
Amino acids are primarily metabolized to urea and other nitrogenous waste products, which are excreted renally (90-95% of total nitrogen excreted as urea). Unmetabolized amino acids in plasma are also filtered and reabsorbed by the kidneys; negligible amounts are excreted unchanged (<5%). Biliary/fecal excretion is minimal (<2%).
Renal, primarily as urea and free amino acids; minimal biliary/fecal elimination.
Category C
Category C
Amino Acid Solution
Amino Acid Solution